Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration

• Status: Not yet recruiting
• Trial end date: 2024-11-01

Summary

This will be a randomized, comparative, parallel, clinical study to assess initial safety and tolerability of CG-P5 peptide eye drops compared to placebo in patients diagnosed with age-related wet macular degeneration

• Phase: Phase 1

Details

• Lead Sponsor: Caregen Co. Ltd.
• Collaborator: CBCC Global Research
• Treatments: Aflibercept